Business Update

Gen-Probe, DiagnoCure provide updates on PCA3 prostate cancer collaboration

Published in Gene Therapy Weekly, June 29th, 2006

Gen-Probe Incorporated (GPRO) and DiagnoCure Inc. (CUR) provided three updates on the companies' collaboration and development programs around the innovative, highly specific PCA3 prostate cancer marker.

First, the companies have amended and expanded the terms of their license and collaboration agreement. In order to explore new market opportunities for PCA3, Gen-Probe has granted DiagnoCure exclusive rights to develop in vivo products, and co-exclusive rights to develop fluorescence in situ hybridization (FISH) products, using the PCA3 gene. DiagnoCure will pay Gen-Probe royalties on any commercial sales of such products.

In addition, the companies...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2006-06-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry